Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (530)	8/2/1999 10:16:00 AM
From: aknahow	Read Replies (1) \| Respond to of 3158

While really not a big deal for Merck, worth noting that Merck among all the large Pharmas always said it had no interest in acquisitions. Everyone else said they were going to do some. The cash offer is not as tax friendly but the largest holders may not have a taxable gain. Wondered why stock did not drop when the disappointing results were reported and I think you have made it clear why it did not. There were, as far as price moves are concerned, no overt leaks of the news, which is interesting, since posters always seem to think this sort of news leaks.

To: Biomaven who wrote (530)	8/2/1999 10:59:00 AM
From: RCMac	Respond to of 3158

>>Significant premium [for SIBI] over the current price, but not a huge win for the third-tier denizens who are in these stocks for the 10-baggers.<< As Andreas Helke noted at the time of the arguably too-cheap SUGN deal: >>I wonder if biotech investing with its enormous price volatility and development risk makes sense when the best companies disappear long before they can show their full potential.<< Message 10334639 This was in reference to SUGN and AGPH, but the SIBI deal raises the issue again. --RCM

To: Biomaven who wrote (530)	8/2/1999 5:05:00 PM
From: RWReeves	Respond to of 3158

I too have Rick to thank for keeping me in SIBI. I liked the science but was discouraged by SIBI's inability to keep above 5 1/2 last few months. When some limit orders bought me some more on a dip two weeks ago, although my first response was- "just what I need, more SIBI". Merck got this one cheap- looks like the technology value was about $60 MM when you net out SIBI's cash. Not what might indicate the start of a feeding frenzy. A somewhat disappointing deal. RWR